Spravato (esketamine) is a nasal spray medication derived from ketamine, used for treatment-resistant depression and acute suicidal ideation or behavior.
It targets the NMDA receptor in the brain, promoting rapid improvement in depression symptoms by enhancing synaptic connections and restoring neural function.
It is for adults with depression who haven’t responded to at least two antidepressants.
Adults who are experiencing severe depressive symptoms with suicidal ideation.
SPRAVATO® has extra safeguards to ensure it’s right for you.
We’re here to guide you every step of the way.

Meet with one of our providers to discuss your mental health history, current symptoms, and treatment goals. During this step, your provider will determine if you meet the criteria for SPRAVATO®, which includes having treatment-resistant depression (TRD) or major depressive disorder (MDD) with acute suicidal ideation or behavior, and a lack of adequate response to at least two prior antidepressant medications. Additionally, any medical conditions, medications, or contraindications will be reviewed to ensure SPRAVATO® is safe for you.

Our support staff will work with your insurance company to confirm coverage and obtain prior authorization. SPRAVATO® offers assistance programs that may help with insurance navigation and financial support.

Further assessments may be conducted to establish a baseline of your symptoms and mental health status. Your physical health will also be assessed, as certain conditions may affect your ability to use SPRAVATO®.

SPRAVATO® must be administered in a certified healthcare facility under medical supervision. During your initial visit, you'll self-administer the nasal spray under the guidance of a healthcare provider and remain in the facility for at least two hours for monitoring to ensure there are no adverse side effects. Common effects like dizziness, dissociation, or sedation will be observed, and appropriate measures taken if needed.

SPRAVATO® is usually administered twice weekly for the first four weeks during the induction phase. After this initial phase, sessions are typically reduced to once weekly, and then potentially to once every two weeks, based on your response and provider recommendations. SPRAVATO® is always used in conjunction with an oral antidepressant.

You’ll have scheduled follow-ups with your provider to track your progress, adjust dosages, and ensure the treatment is effective. Your provider will help you determine the appropriate duration of SPRAVATO® treatment and discuss how it fits into your broader mental health plan, including therapy, lifestyle changes, or other medications.
Find answers to common questions about SPRAVATO® and what to expect.
Spravato (esketamine) is a nasal spray medication derived from ketamine, used for treatment-resistant depression and acute suicidal ideation or behavior.
Spravato targets the NMDA receptor in the brain, promoting rapid improvement in depression symptoms by enhancing synaptic connections and restoring neural function.
Spravato is for adults with depression who haven’t responded to at least two antidepressants or are experiencing severe depressive symptoms with suicidal ideation.
Spravato is a nasal spray administered in a certified healthcare setting under supervision. Clients remain on-site for observation after administration.
Treatment begins with twice-weekly sessions for the first four weeks, then tapers to weekly or biweekly maintenance sessions based on individual needs.
Sessions typically last about 2-3 hours, including administration, observation, and recovery time.
Many individuals report improvements within hours or days, though full effects may take a few sessions.
Common side effects include dizziness, dissociation, nausea, drowsiness, increased blood pressure, or headaches. Most are temporary and subside after the session.
Response varies by individual. If Spravato is not effective, your provider will explore other treatment options.
No, clients must arrange transportation as they cannot drive until the following day.
While esketamine is a controlled substance, the risk of misuse is low due to the supervised administration and controlled dosing.
Spravato is not recommended for individuals with certain medical conditions, such as aneurysms, a history of substance abuse, or uncontrolled high blood pressure.
Yes, Spravato is typically used alongside an oral antidepressant and therapy for a comprehensive approach to treatment.
You’ll self-administer the nasal spray under supervision, then relax in a calm environment for observation. Providers monitor your response and vital signs.
Some clients experience dissociation or feelings of detachment, which typically resolve within the observation period.
Spravato is not recommended during pregnancy or breastfeeding. Discuss risks and alternatives with your provider.
Created by DearDoc.
All Rights Reserved Tidewater Psychotherapy Services